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Abstract
Background: Studies on the impact of time to treatment on myocardial infarct size have yielded conflicting
results. In this study of ST-Elevation Myocardial Infarction (STEMI) treated with primary percutaneous coronary
intervention (PCI), we set out to investigate the relationship between the time from First Medical Contact (FMC) to
the demonstration of an open infarct related artery (IRA) and final scar size.
Between February 2006 and September 2007, 89 STEMI patients treated with primary PCI were studied with
contrast enhanced magnetic resonance imaging (ceMRI) 4 to 8 weeks after the infarction. Spearman correlation
was computed for health care delay time (defined as time from FMC to PCI) and myocardial injury. Multiple linear
regression was used to determine covariates independently associated with infarct size.
Results: An occluded artery (Thrombolysis In Myocardial Infarction, TIMI flow 0-1 at initial angiogram) was seen in
56 patients (63%). The median FMC-to-patent artery was 89 minutes. There was a weak correlation between time
from FMC-to-patent IRA and infarct size, r = 0.27, p = 0.01. In multiple regression analyses, LAD as the IRA, smoking
and an occluded vessel at the first angiogram, but not delay time, correlated with infarct size.
Conclusions: In patients with STEMI treated with primary PCI we found a weak correlation between health care
delay time and infarct size. Other factors like anterior infarction, a patent artery pre-PCI and effects of reperfusion
injury may have had greater influence on infarct size than time-to-treatment per se.
Keywords: Angioplasty, Balloon, Coronary, Emergency Medical Services, Myocardial Infarction, Myocardial Reperfu-
sion, Time Factors, Time and Motion Studies
Background
Reperfusion of the occluded artery in ST elevation myo-
cardial infarction (STEMI) is preferably performed with
primary Percutaneous Coronary Intervention (PCI) and
adjunctive therapy with Glycoprotein (Gp) IIb/IIIa inhi-
bitors even if this requires transportation of the patient
to an institution that performs angioplasty [1-3]. Studies
on the impact of time to treatment on mortality have
revealed conflicting results [4-8]. Recently, Francone et.
al studied 70 patients with STEMI with contrast
enhanced Magnetic Resonance Imaging (ceMRI) and
found that a shorter time to reperfusion was associated
with smaller infarct size. This effect was mainly limited
to patients treated within 90 minutes of symptom onset
[9]. Brodie et al. found similar results when analysing
patients from the EMERALD trial with a greater impact
of the duration of ischemia in anterior versus non ante-
rior infarction [10]. Haase et al. studied 45 STEMI
patients and found no correlation between infarct size
and time from onset of symptoms to PCI [11]. In a
study comparing prehospital fibrinolysis with facilitated
PCI there was a relationship between time to treatment,
infarct size and transmurality [12]. Also Tarantini et al.
found an association between time to treatment and the
risk of a larger scar [13]. We hypothesised that in
patients with STEMI treated with primary PCI and
adjunctive abciximab, time from first medical contact
(FMC) to demonstration of an open infarct related
* Correspondence: timtodt64@gmail.com
1Department of Medical and Health Sciences, Division of Cardiology,
Linköping University, Linköping, Sweden, Department of Cardiology UHL,
County Council of Östergötland, SE-581 85 Linköping, Sweden
Full list of author information is available at the end of the article
Tödt et al. BMC Cardiovascular Disorders 2012, 12:9
http://www.biomedcentral.com/1471-2261/12/9
© 2012 Tödt et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.artery (IRA) is associated with the degree of myocardial
injury measured with ceMRI.
Methods
STEMI strategy in the county of Östergötland
Since 2005 the Heart Centre of Östergötland, serving a
population of 420 000 has adopted a strategy of primary
PCI for all patients with STEMI, with prehospital
administration of abciximab in suitable cases. Patients
who present with symptoms of Myocardial Infarction
(MI) and ST elevation or extensive anterior ST depres-
sion or bundle branch block on the ECG are sent to the
cath-lab with the intention of performing primary PCI.
Pretreatment with acetylsalicylic acid 300 mg orally is
recommended in the absence of contraindications. Bolus
abciximab (0.25 mg/kg), heparin (50 U/kg) and beta
blockers are given at the discretion of the attending phy-
sician. Physicians are encouraged to give pretreatment
with abciximab to patients with clear ST elevation on
t h ed i a g n o s t i cE C Ga n dd i s t i n c ts y m p t o m so fM I .
Patients on warfarin, with a history of bleeding, of old
age, or for other reasons having a high risk for bleeding,
or patients without a clear diagnosis of STEMI are
usually not given abciximab before arrival in the cath
lab. If not given as pretreatment abciximab is given only
after angiography has confirmed occlusion/stenoses sui-
table for PCI.
Study population
Between February 2006 and September 2007, 149
STEMI patients treated with primary PCI at the Heart
Centre of Östergötland and no known contraindication
to ceMRI gave their written informed consent to partici-
pate in the study. Sixty patients were excluded due to
one or more of the following reasons; previous myocar-
dial infarction (7), death before ceMRI (3) reinfarction
(1), new revascularisation with either CABG or PCI (15),
new contraindication to ceMRI (3), lost to follow up (1),
malignancy (1), claustrophobia while in the magnet (4),
inability to perform the whole ceMRI study (2) and
unwillingness to come back to the hospital to perform
the ceMRI study (23). Thus, 89 patients remained for
further analysis. In a broader picture the total number
of primary PCI performed during the study period was
589. Thus, the majority of STEMI patients was not
asked to participate either due to administrative reasons,
long distance to the hospital, early transfer to the local
hospital, early cardiac surgery or other factors prevent-
ing the participation of the patient. One year mortality
was 12.7% in this group.
Magnetic resonance imaging
ceMRI was performed 4-8 weeks after the date of pri-
mary PCI. The patients were placed in the magnet (1.5
T Achieva, Philips Healthcare, Best, the Netherlands) in
supine position. A circular polarized body-array surface
coil was used in all measurements. ECG-triggered MR
images were obtained during repeated breath-holds.
Cine-loops were acquired with a balanced steady state
free precession turbo field-echo (b-SSFP TFE) sequence,
on average 18, (range 10-23) short axis slices and three
long axis planes (apical 2-, 3- and 4-chamber views).
Temporal resolution was in between 26-41 ms (30
acquired phases). The inversion recovery turbo field
echo (IR-TFE) sequence was a segmented 3D spoiled
gradient echo sequence with TE = 1.3 ms, TR = 4.4 ms
and TFE factor 43, leading to an acquisition phase time
of 188 ms during diastole. Slice thickness was 10 mm
intersection gap -5 mm (i.e. slices were overcontiguous),
field-of-view 350 mm and image matrix 128 × 256. The
contrast-enhanced images were acquired at the same
slice positions as the cine-images, about 20 min after
the administration of gadopentetate dimeglumine (Gd-
DTPA) 0.2 mmol/kg bodyweight (Schering Nordiska
AB, Järfälla, Sweden). Optimal contrast between hyper-
enhanced areas and normal myocardium was main-
tained by continually adjusting the inversion time to
null the signal from healthy myocardium, Figure 1. Scar
size was measured by two different observers on short-
axis images using the freely available software “Segment”
http://segment.heiberg.se[14]. Infarct volume and per-
centage was calculated from the short axis stack of
slices. End diastolic myocardial and cavity volumes were
measured from the short axis late gadolinium enhanced
(LGE) images.
Angiography
All angiograms were reviewed by three experienced
PCI operators blinded for all other parts of the study.
The following items were analysed: location of the
acute vessel occlusion, Thrombolysis In Myocardial
Infarction (TIMI) flow before and after intervention,
type of PCI performed, success of treatment, and
extent of coronary artery disease. Disagreement
between observers was solved by consensus. The time
when a patent Infarct Related Artery (IRA) was
obtained was defined as the time of balloon inflation
in patients with TIMI 0-1 flow at the first angiogram.
In patients with TIMI 2-3 flow on arrival, the time of
the first angiogram demonstrating an open culprit
artery was considered as time of patent IRA. First
Medical Contact (FMC) was defined as time when the
patient called the ambulance system for patients
admitted with ambulance directly to the cath lab and
time for arrival to the Emergency Department for
other patients. Patients were followed for one year for
the occurrence of rehospitalisation for angina, myocar-
dial infarction, PCI or CABG and for mortality.
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Ethical Review Board in Linköping and adhered to the
Declaration of Helsinki.
Statistical analysis
Data were analysed with SPSS software, version18.0
(SPSS,Chicago, Illinois). Continuous variables were
reported as mean +/- SD or median (25th-75th percen-
tile) as appropriate. For normally distributed variables
two-tailed Student’s t-test was used to verify differences
between groups. Non-normally distributed variables
were compared using the Mann- Whitney U test. Cate-
gorical variables were expressed as counts (percentage).
Statistical significance was assessed with the Chi Square
or the Fischer’s Exact test. Spearman correlations were
computed for time from FMC to an open IRA and
ceMRI measurements of myocardial scar.
Multiple linear regression analysis was used to deter-
mine independent correlates of infarct size. Variables
included were age, sex, current smoker, kidney func-
tion, diabetes, LAD as the culprit artery, TIMI 0-1
flow at the first angiogram and time from FMC to
demonstration of a patent artery. Variables were
entered simultaneously into the model. All reported p-
values are two sided. P-values < 0.05 were considered
statistically significant.
Results
Patient mean age was 62 years (SD 9.7). All patients had
definite ST elevation on their diagnostic ECG and had
elevated troponins. PCI was performed on a clearly visi-
ble culprit lesion and all patients were discharged with a
diagnosis of myocardial infarction. A minority of
patients (16%) were women. The median time from
F M Ct oa no p e na r t e r yw a s8 9m i n u t e s .A l lb u to n e
patient received abciximab in conjunction with primary
P C Io fw h o m7 9 %w e r ep r e - t r e a t e dw i t ha b c i x i m a b
before arriving at the cath lab. A majority of patients
were admitted directly to the cath lab by ambulance. No
patient was lost to follow up (Table 1). The culprit ves-
sel was the left anterior descending artery (LAD) in
46%, the circumflex artery (CX) in 12% and the right
coronary artery (RCA) in 42% of patients. A patent
artery (TIMI 2 or 3 flow) at the first angiogram was
observed in 33 (37%) patients (Table 2). An example of
an occluded circumflex artery at arrival is seen in Addi-
tional file 1, the flow effect of passing the guide wire in
Additional file 2 and the final effect of balloon inflation
and stent placement in Additional file 3. CeMRI was
performed within 42 days (range 27-65) of the index
infarction. There were no cardiovascular events between
the index myocardial infarction and ceMRI (19 of the
149 patients were excluded due to this criterion). Time
Figure 1 Late gadolinium enhancement of lateral subendocardial scar in the shortaxis view of the left ventricle. Same patient as in
Additional files 1, 2, 3. The time from first medical contact (FMC) to patent artery in this particular patient was 105 minutes.
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lute infarct size measured with ceMRI (Figure 2).
Patients with a patent artery within 90 minutes after
FMC appeared to have smaller infarct size in absolute
and relative terms than those with longer delay times
although this did not reach statistical significance (Table
3). Using multiple regression analysis, LAD as a culprit
vessel.
Table 1 Baseline characteristics
FMC to patent artery < 90 min (N = 48) FMC to patent artery ≥ 90 min (N = 41) P value
Age, years (SD) 61.8 (9.7) 62.9 (9.8) 0.62
Women 5 (10.4) 9 (22.0) 0.14
Risk factors
Diabetes Mellitus 4 (8.3) 1 (2.4) 0.37
Hypertension 12 (25.0) 13 (31.7) 0.48
Current smoker 21 (43.8) 18 (43.9) 0.99
Hyperlipidemia 1 (2.1) 3 (7.3) 0.33
Previous Revascularization 0 (0) 0 (0)
Creatinine clearance ml/min (SD) 81 (23.1) 74 (18.6) 0.60
Clinical presentation
Systolic blood pressure, mmHg (SD) 145 (29.6) 136 (26.4) 0.12
Heart rate, beats/min (SD) 70 (14) 66 (14) 0.18
Presentation off hours 27 (56.3) 32 (78.0) 0.03
Admission with ambulance 44 (91.7) 34 (82.9) 0.21
Pretreatment with abciximab 37 (77.1) 33 (80.5) 0.70
Time delays, median, minutes (IQR)
Symptom to FMC 91 (51-191) 90 (28-229) 0.43
FMC to angiography 66 (58-79) 93 (85-116) 0.0005
FMC to patent artery 78 (68-83) 107 (100-131) 0.0005
FMC to balloon 84 (76-100) 111 (104-140) 0.0005
Symptom to abciximab 150 (80-195) 160 (78-285) 0.48
Abciximab to PCI 53 (33-68) 63 (43-78) 0.13
Data are presented as counts (percentage) if not otherwise indicated. SD Standard Deviation. IQR Interquartile range. FMC, First Medical Contact. Creatinine
clearance calculated Cockroft Gault formula ((140 - Age) * (Wt in kg) * (0.85 if female)/(72 * cr) (Plasma Creatinine * 0.8136)). PCI Percutaneous coronary
intervention
Table 2 Angiographic data
FMC to patent artery < 90 min (N = 48) FMC to patent artery ≥ 90 min (N = 41) P value
Extent of coronary disease
One vessel disease 25 (52.1) 22 (53.7) 0.88
Two vessel disease 15 (31.3) 12 (29.3) 0.84
Three vessel disease 9 (18.8) 6 (14.6) 0.60
Infarct related artery
LAD/Diagonal 24 (50.0) 17 (41.5) 0.42
Cx/Intermediate/Marginal 3 (6.3) 8 (19.5) 0.058
RCA/RPD/Posterolateral 21 (43.8) 16 (39.0) 0.65
TIMI flow at first angiogram
TIMI 0 20 (41.7) 26 (63.4) 0.04
TIMI 1 5 (10.4) 5 (12.5) 1.0
TIMI 2 12 (25.0) 4 (9.8) 0.06
TIMI 3 11 (22.9) 6 (14.6) 0.32
Data are presented as counts (percentage). FMC - First Medical Contact. LAD - Left anterior descending artery. Cx - Circumflex artery. RCA - Right coronary artery.
RPD - Right posterior descending artery. TIMI - Thrombolysis in Myocardial Infarction
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the first angiogram, but not time from FMC to demon-
stration of a patent artery, correlated with infarct size
(Table 4). During one year follow up there was no mor-
tality. A new myocardial infarction occurred in two
patients and a new revascularisation with PCI and/or
CABG was performed in 16 (18%) patients. In patients
with an occluded IRA at presentation in the cath lab (n
= 56) there was no correlation between FMC to an
open vessel (r = 0.13, p = 0.36) and infarct size. There
were 10 patients with no visible scar on ceMRI. These
patients were admitted due to symptoms of an acute
coronary syndrome with ST elevation on their diagnos-
tic ECG. They had a clear culprit lesion treated with pri-
mary PCI that corresponded to the ECG findings. The
peak troponin in this group of patients was 3.5 (0.4-14)
ug/l, (cut off value 0.05 ug/l) and they were discharged
from the initial hospital stay with a diagnosis of myocar-
dial infarction. The patients without detectable scar
were not regarded as aborted infarctions and were
included in the total analysis. Patients with no scar on
ceMRI six weeks after infarction were younger, tended
to have less extensive coronary disease, had shorter time
from FMC to a patent artery and had a TIMI 2-3 flow
at presentation in 80% of cases.
Discussion
In this single centre prospective study of patients with
STEMI we found a weak correlation between First Med-
ical Contact (FMC) to an open IRA (median time 89
minutes) and infarct size measured with ceMRI. Mea-
surements of overall treatment delay could be hampered
by recall bias and measurement error. Therefore, in the
main analysis we have used the robust measure of time
from FMC-to-patent artery [15] instead of symptom-to-
patent artery. However the relationship for total delay
time and infarct size was only marginally weaker (r =
0.21, p = 0.05) than health care delay time and infarct
Figure 2 Relationship between time (minutes) from first medical contact (FMC) to an open Infarct Related Artery (IRA) and absolute
scar size (ml), r = 0.27, p = 0.01.
Table 3 Cardiac Magnetic Resonance data
FMC to patent artery < 90 min (N = 48) FMC to patent artery ≥90 min (N = 41) P value
Scar% 4 (1-14) 8 (4-13) 0.06
Scar ml 6 (1-18) 12 (6-19) 0.07
Data are presented as median with interquartile range. FMC, First Medical Contact
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restricted to patients with an occluded artery at presen-
tation, i.e. TIMI 0-1 flow, we found no correlation
between time from symptom onset, (r = 0.12, p =0 . 3 8 ) ,
or FMC to a patent IRA (r = 0.13, p = 0.36) and infarct
size. Patients who demonstrated a patent artery within
90 minutes of FMC showed a trend towards smaller
infarct size than those who presented with longer delay
times. Moreover, among 10 patients with no infarct
detectable on ceMRI all but one had a FMC-to-patent
artery time less than 80 minutes. Several studies have
shown a correlation between time to treatment and
mortality [16-18] as well as between time to treatment
and myocardial salvage and damage measured with Sin-
gle Photon Emission Computed Tomography (SPECT)
or ceMRI [19,20]. Intuitively, we expect an association
between time delay and scar size. Several mechanisms
that dilute this association may be in operation and
need to be accounted for, such as variable effects of
reperfusion injury which may be responsible for as
much as 25% of final infarct size [21]. The circum-
stances governing effects of reperfusion are only partly
known [22]. In a pooled analysis of four contemporary
primary PCI trials, Stone et al. showed longer symptom-
onset-to-balloon time to be associated with larger infarct
size measured with SPECT. Specifically there was a ben-
efit in patients reperfused within three hours of coron-
ary occlusion. In patients with PCI less than two hours
after symptom onset infarct size was very small, being
only 4% of the left ventricular myocardium [23]. These
results are in line with a study by Hedström et al. who
provided evidence that infarct size increased with the
duration of ischemia in their population with an
occluded artery [24]. There are several reasons why the
correlation between time from FMC to open artery and
scar size was weak in our study. A substantial number
(37%) showed TIMI 2-3 flow in the IRA on the first
angiogram [25]. The true time to spontaneous opening
of the IRA is most likely shorter than the time attribu-
ted to those patients in the study. This fact may dilute
the relationship between time delay and scar size. In
patients with TIMI 2-3 flow at angiograpy, 82% received
abciximab already in the ambulance. Moreover, these
patients had significantly smaller infarct size measured
on ceMRI (7 vs. 17 ml, p <0 . 0 0 1 )a n d8o u to f3 3
patients with a patent IRA on arrival had no sign of
myocardial scar at all. The benefit of a normal epicardial
blood flow in the IRA before PCI has been documented
in numerous studies [26-30]. Antegrade flow in the IRA
has been associated with smaller infarct size [23,31,32]
and could weaken the effect of longer health care delay
time. The median time from symptom-to-angiography
in our study was189 minutes which also is the median
time for the whole population of STEMI patients treated
with primary PCI in Sweden [33]. The total time delay
to primary PCI in our population was 193 minutes. As
shown in the study by Stone [23] and supported by
experimental results [34] there is less effect on infarct
size when PCI is performed two to three hours after
coronary occlusion. Moreover, Francone et.al showed
that myocardial salvage was detectable mainly in
patients reperfused within 90 minutes after symptom
onset [9] which was achieved in only three of our
patients. Additionally, the median infarct size was small,
7% of LV mass, probably reflecting that the study popu-
lation represented a healthier part of the wider spectrum
of STEMI patients which reduces the possibility to
demonstrate significant differences between groups
based on the time delay to opening the vessel. Lastly, we
cannot rule out that in a larger study population we
would have seen a stronger correlation between time to
treatment and infarct size.
The influence of the infarct related artery
Patients with infarctions within the LAD territory had
significantly shorter time from symptom onset to FMC
(60 vs 130, p =0 . 0 1 )b u tn od i f f e r e n c ei nF M Ct oP C I
or a patent artery. (88 vs 89, p = 0.44). This could be
interpreted in terms of a larger ischemic area producing
more intense symptoms prompting patients to seek
medical attention. The patients with LAD as the culprit
artery actually developed larger infarct size, 16 ml vs. 9
ml, p = 0.02, despite shorter time to treatment [35,36].
Multiple regression analyses revealed LAD as the culprit
artery, active smoking and an occluded vessel at the first
angiogram to correlate with infarct size. This could be
due to several factors such as, a) the LAD perfuses a lar-
ger myocardial territory than other vessels [37], b) the
scar size from a maintained occlusion with a late reper-
fusion injury could be larger than from a shorter
ischemic time combined with an early reperfusion, c)
active smoking could be related to more advanced
Table 4 Multiple linear regression.
B (95% CI) P value
Variable
Age 0.99 (-23-22) 0.96
Occluded artery at first angiogram 11 (5-17) 0.0005
LAD as culprit artery 11 (5-17) 0.0005
FMC to patent artery (minutes) 0.02 (-0.06-0.09) 0.61
Active Smoker 7 (1-13) 0.02
Male sex 4 (-3-12) 0.26
eGFR -0.1 (-0.3-0.1) 0.23
Diabetes 1 (-10-13) 0.82
Predictors of infarct size (Scar ml)
B, regression coefficient. CI, confidence interval. FMC - First Medical Contact.
LAD, Left anterior descending artery. eGFR,estimated glomerular filtration rate
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the chance of spontaneous thrombolysis [38].
Limitations of the study
Only patients who survived the initial hospital stay and
were free from a cardiac event during the interim period
were included. CeMRI was performed on average six
weeks after myocardial infarction and not in the early
phase of infarction. However, studies have shown that
infarct size measured with ceMRI is largest in the acute
phase and diminishes gradually [39]. After 10 days the
contrast enhanced area seems to be quite stable and
allows reproducible measurement of the size of the final
myocardial damage even if later shrinkage of scar is pos-
sible [40]. The median symptom-to-patent artery time
was more than three hours and only three patients were
treated within 90 minutes of symptom onset, which is
the new gold standard proposed by the study by Fran-
cone et al. [9]. However the time delays in our study are
not longer than measured in many other trials [23]. In
addition, for patients with an open vessel at angiogra-
phy, the time to open artery was taken as the time of
the angiography, even if spontaneous opening of the
vessel may have occurred earlier.
Conclusions
In STEMI patients treated with primary PCI we found a
weak correlation between FMC to demonstration of an
open IRA and myocardial injury on ceMRI six weeks
later. In this study, other factors like anterior infarction,
a patent artery at the initial angiogram and effects of
reperfusion injury seem to have greater influence on
infarct size than time to treatment per se.
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